Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 15-16/2014

01.08.2014 | original article

Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease

verfasst von: MD Ivana Mikolasevic, Lidija Orlic, Sandra Milic, Vesna Lukenda, Sanjin Racki, Davor Stimac, Ervin Avdovic, Luka Zaputovic

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2014

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background/aim

The relationship between nonalcoholic fatty liver disease (NAFLD) and coronary heart disease (CHD) is poorly understood. In the present study, we aimed to assess the frequency of NAFLD in CHD patients by using a new diagnostic tool: transient elastography (TE; Fibroscan®-CAP). Clarification of the present study may help to provide a new noninvasive tool for the assessment of NAFLD in this specific population of patients and may be of clinical importance in planning preventive strategies in high-risk patients.

Patients and methods

A total of 75 patients with proven CHD were enrolled. Liver stiffness was used to assess liver fibrosis, and controlled attenuation parameter (CAP) was used to detect and quantify liver steatosis by using Fibroscan® (Echosens, Paris, France). By CAP being implemented on TE, both liver steatosis and fibrosis can be evaluated simultaneously.

Results

Of the 75 patients, 45 (60 %) had CAP > 238 dBm−1 and, by definition, NAFLD. Among the patients with NAFLD, 24 (53.3 %) had, in addition, liver stiffness > 7 kPa. Analyzing the influence of the degree of liver steatosis (expressed by CAP values) on the degree of CHD (defined by single or multiple vessels involved), we found that patients with multiple vessels involved had higher CAP values (p = 0.002). Furthermore, we noticed that significantly more patients with multiple vessels involved had liver stiffness > 7 kPa (p < 0.0001) indicating the more severe form of NAFLD in those patients.

Conclusion

The main finding of our study is that TE provides the opportunity of noninvasive screening for NAFLD in CHD patients, as it is a quick, simple, reliable, and repeatable method and more cost-effective than liver biopsy.
Literatur
1.
Zurück zum Zitat Milic S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis. 2012;30:158–62. PubMedCrossRef Milic S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis. 2012;30:158–62. PubMedCrossRef
2.
Zurück zum Zitat Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 2008;51:1947–53. PubMedCrossRef Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 2008;51:1947–53. PubMedCrossRef
3.
Zurück zum Zitat Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473–80. PubMedCrossRef Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473–80. PubMedCrossRef
4.
Zurück zum Zitat Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525–40. PubMedCentralPubMedCrossRef Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525–40. PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235–40. PubMedCrossRef Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235–40. PubMedCrossRef
6.
Zurück zum Zitat Kim CH, Younossi ZM. Non alcoholic fatty liver disease: a manifestation of metabolic syndrome. Cleve Clin J Med. 2008;75:721–8. PubMedCrossRef Kim CH, Younossi ZM. Non alcoholic fatty liver disease: a manifestation of metabolic syndrome. Cleve Clin J Med. 2008;75:721–8. PubMedCrossRef
7.
Zurück zum Zitat Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med. 2007;24:1–6. PubMedCrossRef Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med. 2007;24:1–6. PubMedCrossRef
8.
Zurück zum Zitat Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:325–35. PubMedCrossRef Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:325–35. PubMedCrossRef
9.
Zurück zum Zitat Chowdhury SD, Ramakrishna B, Eapen CE, Goel A, Zachariah UG, Chandramohan A, et al. Fibrosis in non-alcoholic fatty liver disease: correlation with simple blood indices and association with tumor necrosis factor-alpha polymorphisms. Trop Gastroenterol. 2013;34:31–5. PubMedCrossRef Chowdhury SD, Ramakrishna B, Eapen CE, Goel A, Zachariah UG, Chandramohan A, et al. Fibrosis in non-alcoholic fatty liver disease: correlation with simple blood indices and association with tumor necrosis factor-alpha polymorphisms. Trop Gastroenterol. 2013;34:31–5. PubMedCrossRef
10.
Zurück zum Zitat Celikbilek M, Dogan S, Gursoy S, Zararsız G, Yurci A, Ozbakır O, et al. Noninvasive assessment of liver damage in chronic hepatitis B. World J Hepatol. 2013;5:439–45. PubMedCentralPubMedCrossRef Celikbilek M, Dogan S, Gursoy S, Zararsız G, Yurci A, Ozbakır O, et al. Noninvasive assessment of liver damage in chronic hepatitis B. World J Hepatol. 2013;5:439–45. PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol. 2007;46:775–82. PubMedCrossRef Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol. 2007;46:775–82. PubMedCrossRef
12.
Zurück zum Zitat Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:782–9. PubMedCrossRef Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:782–9. PubMedCrossRef
13.
Zurück zum Zitat Sasso M, Beaugrand M, dee Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825–35. PubMedCrossRef Sasso M, Beaugrand M, dee Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825–35. PubMedCrossRef
14.
Zurück zum Zitat Wong Lai-Hung G. Update of liver fibrosis and steatosis with transiet elastography (Fibroscan ®). Gastroenterol Rep. 2013:1–8. doi:10.1093/gastro/got007. Wong Lai-Hung G. Update of liver fibrosis and steatosis with transiet elastography (Fibroscan ®). Gastroenterol Rep. 2013:1–8. doi:10.1093/gastro/got007.
15.
Zurück zum Zitat Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–52. PubMedCrossRef Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–52. PubMedCrossRef
16.
Zurück zum Zitat Inci MF, Özkan F, Ark B, et al. Sonographic evaluation for predicting the presence and severity of coronary artery disease. Ultrasound Q. 2013;29:125–30. PubMedCrossRef Inci MF, Özkan F, Ark B, et al. Sonographic evaluation for predicting the presence and severity of coronary artery disease. Ultrasound Q. 2013;29:125–30. PubMedCrossRef
17.
Zurück zum Zitat Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5:1544–60. PubMedCentralPubMedCrossRef Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5:1544–60. PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists. J Obes. 2012;2012:483135. Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists. J Obes. 2012;2012:483135.
19.
Zurück zum Zitat Schindhelm RK, Diamant M, Bakker SJ, et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest. 2005;35:369–74. PubMedCrossRef Schindhelm RK, Diamant M, Bakker SJ, et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest. 2005;35:369–74. PubMedCrossRef
20.
Zurück zum Zitat Goland S, Shimoni S, Zornitzki T, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol. 2006;40:949–55. PubMedCrossRef Goland S, Shimoni S, Zornitzki T, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol. 2006;40:949–55. PubMedCrossRef
21.
Zurück zum Zitat Targher G, Bertolini L, Padovani R, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006;29:1325–30. PubMedCrossRef Targher G, Bertolini L, Padovani R, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006;29:1325–30. PubMedCrossRef
22.
Zurück zum Zitat Fracanzani AL, Burdick L, Raselli S, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med. 2008;121:72–8. PubMedCrossRef Fracanzani AL, Burdick L, Raselli S, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med. 2008;121:72–8. PubMedCrossRef
23.
Zurück zum Zitat Cervera-Lizardi J, Zapata-Aguilar D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol. 2009;8:40–3. Cervera-Lizardi J, Zapata-Aguilar D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol. 2009;8:40–3.
24.
Zurück zum Zitat Schwimmer JB, Deutsch R, Behling C, et al. Fatty liver as a determinant of atherosclerosis. Hepatology. 2005;42:610A (abstract). Schwimmer JB, Deutsch R, Behling C, et al. Fatty liver as a determinant of atherosclerosis. Hepatology. 2005;42:610A (abstract).
Metadaten
Titel
Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease
verfasst von
MD Ivana Mikolasevic
Lidija Orlic
Sandra Milic
Vesna Lukenda
Sanjin Racki
Davor Stimac
Ervin Avdovic
Luka Zaputovic
Publikationsdatum
01.08.2014
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2014
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-014-0538-0